nephropathy did not show significant remission of nephrotic proteinuria after treatment with interferonBackground. The relationship between hepatitis C virus (HCV ) infection and acute or chronic glomerulo-alpha. Our data do not appear to support an association between HCV and non-cryoglobulinaemic GN. nephritis (GN ) is not well understood. Methods. Two hundred and eighty-four patients with Further epidemiological surveys, experimental studies and clinical trials are warranted to fully elucidate the biopsy-proven GN and other renal diseases were studied in a multicentre survey performed during the role of HCV in non-cryoglobulinaemic GN. period 1992GN. period -1995 ized the association between HCV infection, essential and significantly associated with anti-HCV antibody. mixed cryoglobulinaemia, and its principal renal lesion, At the completion of treatment with interferon-alpha, cryoglobulinaemic membranoproliferative GN. 67% (2/3) of patients with membranous nephropathy
In addition, three patients with HCV-related liver Introduction disease, membranous nephropathy, and proteinuria in the nephrotic range received therapy with interferonThe hepatitis C virus (HCV ) is an RNA virus recogalpha in standard doses.
nized as the major cause of transfusion-associated [1] Results. The prevalence of anti-HCV positivity was and 'community-acquired' [2] non-A, non-B hepatitis. 13% (38/284) . The frequency of anti-HCV positivity Patients with chronic HCV infection are at risk to ranged between 0 and 100% in the different types of develop chronic active hepatitis, cirrhosis, and hepatorenal diseases, the difference was statistically significant cellular carcinoma [3] . Moreover, numerous extrahep-(P=0.0001). The anti-HCV rate was significantly atic manifestations of HCV infection have been higher in patients with cryoglobulinaemic membranopreviously reported including porphyria cutanea tarda proliferative and mesangioproliferative GN than [4, 5] , Hashimoto's disease [6, 7] and lymphocytic sialaamong the other individuals (14/14 (100%) vs 24/270 denitis [8, 9] . In addition, several epidemiological (9%), P=0.0002). Our multivariate analysis by logistic investigations [10] [11] [12] [13] [14] , case reports [15] [16] [17] [18] [19] [20] [21] [22] [23] , clinical regression model showed that age (P=0.0017) and trials [24] and experimental results [25] have emphastype of renal diseases (P=0.0007) were independently ized the association between HCV infection, essential and significantly associated with anti-HCV antibody.
mixed cryoglobulinaemia, and its principal renal lesion, At the completion of treatment with interferon-alpha, cryoglobulinaemic membranoproliferative GN. 67% (2/3) of patients with membranous nephropathy
In contrast, data from investigations into the relahad lowering of hepatic enzyme levels into the normal tionship between HCV infection and non-cryoglobulrange whereas 100% (3/3) of these did not show inaemic membranoproliferative GN, membranous significant reduction of proteinuria.
nephropathy, or other glomerular diseases are scarce Conclusions. We observed strong association between and with conflicting results. Recently, some sero-HCV infection and cryoglobulinaemic GN. Age and logical investigations from Europe [26] [27] [28] [29] with biopsy-proven glomerulonephritis and other renal anti-c22-3, anti-c33, anti-5-1-1, anti-c100-3). The results diseases. In addition, we treated three patients pre-obtained by RIBATM HCV 2.0 SIA were interpreted as senting HCV-related liver disease, membranous recommended by others [43] . nephropathy, and nephrotic proteinuria with inter-
Hepatitis B surface antigen was tested with commercially feron-alpha as a therapy for the liver and kidney available radioimmunoassay (Abbott Laboratories, North diseases.
Chicago, IL).
Virological assays

Subjects and methods
In anti-HCV-positive samples the presence of HCV RNA
Study design
was detected by reverse-transcription polymerase chain reaction (RT-PCR). We used Amplicor HCV test (Roche We collected the clinical and histological features of the Diagnostic Systems, Nutley, NJ ), as previously reported by patients who consecutively underwent renal biopsy at four others [44] , using primer sets from the 5∞ untranslated region Nephrology Units of Northern and Central Italy during the of the HCV genome. The HCV genotypes in the serum period 1992-1995. The following information in all patients samples of anti-HCV positive samples were detected by a at the same time as the renal biopsy was reported: gender, hybridization assay, called line probe assay (LiPA, age, proteinuria (normal range <0.15 g/24 h), serum creatin-Innogenetics, Zwijndrecht, Belgium), based on the reverseine (normal range 53-115 mmol/l ), detectable serum cryoglo-hybridization principle [45] . HCV genotypes were classified bulins, patient allocation among centres, HBsAg status, and using the nomenclature of Simmonds et al. [46 ] . histology of renal disease. There were 41 (14%) patients from Unit 1, 108 (38%) from Unit 2, 51 (18%) from Unit 3, and
Renal histology
84 (30%) from Unit 4.
Among the patients (n=108) referred to the Unit 2 Renal tissue was obtained by percutaneous renal biopsy in (Nephrology and Dialysis Division of Lecco Hospital ) we all patients. The kidney-biopsy specimen obtained from each identified three patients with HCV-related liver damage, patient was divided into three parts for light microscopy, membranous nephropathy, and proteinuria in the nephrotic direct immunofluorescence, and electron microscopic studies. range. They were treated with 3 million units of lymphoblasThese analyses were made with standard procedures. toid interferon-alpha ( Wellferon, Wellcome) given subcutaneously three times per week for time periods as reported below.
Statistical analysis Study group
Data are expressed as mean±standard deviation. Nonparametric data are expressed as median with respective There were 181 males and 103 females, the mean age of the patients was 51.2±23 years, the median value of proteinuria ranges. Group comparisons were made by Student's t test for parametric data and Mann-Whitney test for nonwas 2.5 g/24 h (range 0-21.9), the median level of serum creatinine was 111 mmol/l (range .
parametric data. Chi-square test with Bonferroni's correction was used for comparison of anti-HCV prevalence in the In our study group we have identified a subgroup (n= 205) of cases of primary GN: IgA nephropathy (n=61), different patient groups. A multivariate analysis with nominal logistic technique was conducted. A nominal regression by minimal-change disease (n=24), focal sclerosing GN (n= 39), membranoproliferative GN (n=10), membranous maximum likelihood for a single nominal response was performed. In our model anti-HCV positivity was included nephropathy (n=55), diffuse mesangioproliferative GN (n= 13), and crescentic GN (n=3). There was a second subset as the dependent variable; gender, age, proteinuria, serum creatinine, HBsAg status, patient allocation among centres, (n=79) of patients with secondary GN and other renal diseases, as follows: diabetic glomerulosclerosis (n=4), cryo-and type of renal disease were predictor variables. Two categories of renal disease were included in the model: globulinaemic GN (n=14), lupus nephritis (n=12), primary GN (n=205) and secondary GN or other nephro-with cryoglobulinaemic GN, non-cryoglobulinaemic pathies (n=79). A P value of less than 0.05 was used to membranoproliferative GN, and membranous nephroindicate statistical significance. Statistical analysis was per-pathy was significantly higher than in the other formed using the statistical package JMP IN, MacIntosh patients, 26/79 (33%) vs 12/205 (6%), P=0.0002.
format, version 3.1.7, ©SAS Institute Inc, USA.
The clinical features of anti-HCV-positive and anti-HCV-negative patients are reported in Table 2 . As shown in Table 2 , only age was significantly higher
Results
in anti-HCV-positive than in anti-HCV-negative individuals.
Epidemiological survey
Univariate analysis. The prevalence of HBsAg positiv-Multivariate analysis ity was 3% (9/284).
Application of a logistic regression model to our group The prevalence of anti-HCV antibody was 13%
showed that age (P=0.0017) and type of renal disease (38/284) in the whole population. There were 38 (13%) (P=0.0007) were independent predictors of anti-HCV of 284 patients positive by ELISA HCV 2.0 and positivity ( Table 3) . The other parameters included in confirmed by RIBA TM HCV 2.0 SIA. Twenty-nine the model did not show significant and independent (76%) of 38 were positive by RIBATM HCV 2.0 SIA, association with anti-HCV antibody. and 9 (24%) of 38 gave 'indeterminate' reactivity by RIBATM HCV 2.0 SIA. Twenty-eight (74%) of 38 were tested by RT-PCR, 21 (75%) of 28 were positive by The frequency of anti-HCV positivity among patients The patient was started on 3 million units of interpulsed corticosteroid therapy with no improvement of feron-alpha three times weekly and treated for 6 renal function or proteinuria.
months. At the end of the treatment period his urinary He was followed up in the outpatient clinic at Lecco protein excretion was 7.6 g/24 h, the creatinine was Hospital until July of 1994 when he was admitted 68.9 mml/l, creatinine clearance 1.82 ml/s, serum albuagain to the Nephrology Division. Laboratory min was 17.4 g/l. AST 0.37 and ALT 0.52 mkat/l, he examination (July 1994) showed: serum creatinine was negative by RT-PCR technique. Serum creatinine 102 mmol/l, creatinine clearance 1.74 ml/s, proteinuria and urinary protein remained stable 1 year after com-10.8 g/24h, a serum albumin (normal range 38-45 g/l )
pletion of interferon-alpha therapy; hepatic enzymes of 28 g/l. AST (normal range <0.67 mkat/l ) and ALT rose slightly, with AST and ALT of 0.68 and 0.98 mkat/l (normal range <0.75 mkat/l ) values were 2.1 mkat/l respectively. and 3 mkat/l respectively. He was found to be HCV antibody positive (anti-HCV ELISA-2 positive; RIBATM HCV 2.0 Strip Immunoblot Assay (SIA) positive), HBsAg negative, anti-HBc negative, antiPatient 3 HBs positive, and HIV negative. Prothrombin time (PT ) and complement studies (C3, C4) were normal, Patient 3 is a 61-year-old white male who presented to rheumatoid factor (RF ) and cryoglobulins negative. the Nephrology Division of Lecco Hospital in March His physical examination was remarkable for hepato-of 1994 with pitting oedema and nephrotic-range promegaly, lower-extremity oedema, and ascites.
teinuria. He denied a history of lupus, diabetes, nonThe patient was placed on 3 million units of inter-steroidal anti-inflammatory drug use, kidney disease, feron-alpha three times per week (7.94). At initiation hepatitis or blood transfusions. His hypertension was of treatment, his creatinine was 99.9 mmol/l with 10.8 g well controlled with low-dose loop diuretics prior to urinary protein/24 h, and a creatinine clearance of and throughout alpha-interferon therapy. Laboratory 1.73 ml/s. AST and ALT levels were 1.7 and 1.8 mkat/l studies were significant for the following: proteinuria respectively; he tested positive by RT-PCR and showed 9.7 g/24 h, serum creatinine 57.5 mmol/l, creatinine genotype HCV 1b. After 5 months interferon-alpha clearance 2.09 ml/s. Antinuclear antibody (ANA) and was stopped because of fatigue, nausea, and headache; cryoglobulins negative, rheumatoid factor (RF ) negathe patient's urinary protein excretion was 7.2 g tive, C3 and C4 0.8 and 0.26 g/l respectively. AST 1.2 protein/24 h, liver enzymes were normal (AST and ALT 2.7 mkat/l, albumin 24 g/l. HCV antibody 0.45 mkat/l and ALT 0.32 mkat/l ), creatinine remained positive (second-generation ELISA and RIBATM SIA), at 97.2 mmol/l, creatinine clearance was 1.65 ml/s. He HBsAg negative, HIV negative. He showed HCV RNA was viraemic by RT-PCR. After discontinuing alphaby RT-PCR and had HCV genotype 1b. A renal biopsy interferon, serum aminotransferase levels remained was performed in March of 1994 which revealed memstable for 1 year.
branous nephropathy (stage II-III ). A liver biopsy at the same time as the renal biopsy was consistent with Patient 2 chronic active hepatitis showing mild piecemeal necrosis. Patient 2 is a 50-year-old white male with a history of
The patient was started on 3 million units of myocardial infarction and porphyria cutanea tarda.
interferon thrice weekly. At the end of the treatment The patient denied a history of lupus, diabetes, nonwith interferon-alpha, proteinuria was 9.5 g/24 h and steroidal anti-inflammatory drug use, kidney disease, serum creatinine was 53.9 mmol/l, creatinine clearance or blood transfusions. He had had raised amino-1.83 ml/s. Liver enzymes remained elevated (AST 0.83 transferase levels since 1993; he then suspended alcohol use. The patient was referred to the Nephrology and ALT 1.65 mkat/l ). He tested positive by RT-PCR.
The high anti-HCV prevalence we observed in Discussion patients with membranous nephropathy and noncryoglobulinaemic membranoproliferative GN is Although it is well known that hepatitis B virus may rather difficult to evaluate as these patient subgroups cause GN [47] , mainly membranous and membranowere not very large (n=55 and 10 respectively); but it proliferative GN, HCV-related GN has been only might be interesting in the light of the recent evidence recently reported. In addition to cryoglobulinaemic [13, [33] [34] [35] [36] [37] [38] [39] [40] indicating that HCV may be a major cause membranoproliferative GN [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and IgA nephroof non-cryoglobulinaemic GN. In contrast, our multipathy [48] , HCV infection has been described in associvariate analysis emphasized the importance of age as ation with 'idiopathic' membranoproliferative GN independent predictor of anti-HCV antibody in our [13, 33] , membranous nephropathy [33-34, [36] [37] [38] [39] [40] mespopulation. Also in the general population the antiangioproliferative GN [41] , focal sclerosing [33] , and HCV prevalence increases [54] with age, as did HBV fibrillary GN [35] . Moreover, several cases of de novo markers. In addition, the type of renal disease was hepatitis C-associated GN have been recently reported significantly and independently associated with antiin HCV-infected patients after bone marrow [38] , liver HCV in our multivariate analysis; this is probably [16, 49] , and kidney [50] [51] [52] [53] transplantation, only some related to the very high rate (100%) of anti-HCV of them showing cryoglobulinaemia or rheumatoid among patients with cryoglobulinaemic GN. factor.
Our epidemiological investigation and clinical trial In our multicentre study we showed a very strong appear to confirm the hypothesis that the association association (100% rate) between cryoglobulinaemic between non-cryoglobulinaemic GN and HCV does GN and HCV, as detected by anti-HCV testing. not exist in Europe. In contrast, the experience accumuMoreover, we found a high prevalence of anti-HCV in lated in USA [13, 34, 35] and Saudi Arabia [33], implies patients with non-cryoglobulinaemic membranopro-a role of HCV in non-cryoglobulinaemic GN. Likewise liferative GN and membranous nephropathy (20 and HCV-associated GN, HBV-associated GN has been 18% respectively). Even when corrected for age, the frequently reported in some geographical areas, such prevalence of HCV infection in comparable general as Poland [57], Korea [58], Japan [59] , and Africa population of the Milan area [54] is only about 7%. [60] , but it is rare in the United States [61, 62] and In accordance with such data and the recent evidence Western Europe [47] . We are planning to study the accumulated in the literature [33] [34] [35] , we treated three predictors of anti-HCV positivity in larger cohorts of anti-HCV-positive patients presenting HCV-related subjects with biopsy-proven glomerular diseases. liver disease, membranous nephropathy, and nephrotic
One possibility is that in some cases of hepatitis-Cproteinuria with interferon-alpha in standard doses. In associated GN who have neither tissue nor serological contrast with the results obtained by Arabian [33] and evidence of cryoglobulins, the production of cryoglobuAmerican [34, 35] investigators, patients of our series lins might not reach a level that would be easily did not show improvement of renal function after detected by standard laboratory techniques. Also, some therapy with interferon-alpha. Furthermore, two patients with HCV-associated GN might produce antipatients had lowering of hepatic enzyme levels into the body with the biological features of 'rheumatoid factor' normal range at the end of the treatment, this is but without the ability to induce immune complex probably related to the interferon-alpha activity. Thus, precipitable in the cold. Alternatively, these individuals in these two patients the unchanged levels of pro-could develop an immunocomplex GN with no detectteinuria at the end of the therapy are not probably able circulating cryoglobulins. In our survey, testing related to a poor responsiveness of HCV genotype to for cryoglobulins in serum was performed at the time interferon.
of renal biopsy in all patients; a longitudinal observaSuch lines of evidence do not appear to support an tion over the ensuing months could detect circulating aetiological role of HCV in the development of mem-cryoglobulins in additional individuals, as has previbranous nephropathy in our population. Other thera-ously occurred [24] . However, it might be possible that peutic options in these individuals include a second we are not simply missing the cryoglobulins in the course of interferon-alpha perhaps in a higher dosage serum of some patients with HCV-associated GN. or for a prolonged period. A sustained clinical remis-Indeed, it has been postulated [63] that only antision following therapy with high-dose interferon-alpha HCV-positive patients who produce non-neutralizing has been recently observed in one patient with HCV-antibodies develop some form of glomerulopathy, and associated cryoglobulinaemic membranoproliferative the different patterns of glomerular injury observed so GN [55]. This may not be an option in some patients far may be related to the appropriateness of the because of intolerable side-effects. Alternatively, the immune response to HCV. The precise mechanisms use of a second antiviral agent to potentiate or add to responsible for a virus-induced nephropathy in humans the activity of interferon-alpha or the adoption of a have been only partially elucidated to date [47] , and different type of interferon would be promising. On these suggestions remain speculative. the other hand, an improvement in renal function after
In patients with IgA nephropathy, focal sclerosing treatment with interferon has been reported in some and proliferative mesangial GN, and minimal-change but not all patients with HBV-associated membranous disease, the prevalence of HCV infection was low, ranging between 0 and 6%. This result is in agreement nephropathy [56 ] .
infection and membranoproliferative glomerulonephritis in with the epidemiological investigations made in Europe Japan. J Am Soc Nephrol 1995; 6: 220-223 so far [26, 28] . The anti-HCV prevalence was null in 15. Albarracin C, Gomez Campdera FJ, Lopez Gomez JM, Perez our patients with lupus nephritis, in contrast with Successful cyclophosphamide treatment of cryoglobulinemic
